AIManage for Diabetes and Obesity
What You Need to Know Before You Apply
What is the purpose of this trial?
The objective of this project is to define and test the GenAI-powered Clinical Decision Support (CDS) tool, AIManage, providing a broad range of incretin mimetic medication management services to optimize dose titrations. The study will take place across primary care and obesity medicine clinics at NYUH.
The study is currently conducting formative data collection for tool refinement (Phase 1). Once completed, a cluster randomized controlled trial of the AIManage tool will be undertaken (Phase 2).
Who Is on the Research Team?
Elizabeth Stevens, PhD, MPH
Principal Investigator
NYU Langone Health
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Formative Data Collection
Formative data collection for tool refinement, focusing on perceived usefulness, usability, use challenges, and value
Cluster Randomized Controlled Trial
Testing the AIManage tool in a cluster randomized controlled trial setting
Follow-up
Participants are monitored for safety and effectiveness after the trial
What Are the Treatments Tested in This Trial?
Interventions
- AIManage
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Providers prescribing IMM for at least 5 adult patients in primary care and obesity medicine clinics.
Adult patients prescribed an IMM in the past 6 months.
Find a Clinic Near You
Who Is Running the Clinical Trial?
NYU Langone Health
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.